Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
3.35 (USD) • At close January 7, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Current Assets: | ||||||||
| Cash & Cash Equivalents
| 67.449 | 121.966 | 121.966 | 67.271 | 37.598 | 45.716 | 42.045 | 32.269 |
| Short Term Investments
| 5.002 | 0 | 35.162 | 35.162 | 96.19 | 66.917 | 0 | 0 |
| Cash and Short Term Investments
| 72.451 | 121.966 | 121.966 | 102.433 | 133.788 | 112.633 | 42.045 | 32.269 |
| Net Receivables
| 39.197 | 30.83 | 17.456 | 6.875 | 4.693 | 2.869 | 1.199 | 0.101 |
| Inventory
| 38.838 | 24.735 | 24.735 | 18.118 | 8.353 | 0 | 0 | 0 |
| Other Current Assets
| 5.778 | 9.287 | 4.589 | 3.196 | 5.065 | 2.397 | 0.809 | 0.804 |
| Total Current Assets
| 156.264 | 186.818 | 186.818 | 142.596 | 152.212 | 117.899 | 44.053 | 33.174 |
| Non-Current Assets: | ||||||||
| Property, Plant & Equipment, Net
| 29.175 | 28.375 | 28.375 | 6.627 | 6.707 | 2.034 | 0.788 | 0.312 |
| Goodwill
| 22.859 | 120.607 | 120.607 | 22.859 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 109.764 | 3.992 | 3.992 | 131.45 | 0 | 0 | 0 | 0 |
| Goodwill and Intangible Assets
| 132.623 | 124.599 | 124.599 | 154.309 | 0 | 0 | 0 | 0 |
| Long Term Investments
| 0 | 4.348 | -0.364 | 0 | 13.231 | 0 | 0 | 0 |
| Tax Assets
| 0 | 0.115 | 0.364 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets
| 4.54 | 0.267 | 4.73 | 0.829 | -12.999 | 0.095 | 0.157 | 0.047 |
| Total Non-Current Assets
| 166.338 | 157.704 | 157.704 | 161.765 | 6.939 | 2.129 | 0.945 | 0.359 |
| Total Assets
| 322.602 | 344.522 | 344.522 | 304.361 | 159.151 | 120.028 | 44.998 | 33.533 |
| Liabilities & Equity: | ||||||||
| Current Liabilities: | ||||||||
| Account Payables
| 11.565 | 4.606 | 8.924 | 3.117 | 5.603 | 0.866 | 1.976 | 1.315 |
| Short Term Debt
| 3.495 | 3.16 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue
| 0 | 64.777 | 0 | 0 | 0 | 0.232 | 0.234 | 0.263 |
| Other Current Liabilities
| 80.133 | 65.855 | 70.116 | 25.09 | 21.735 | 9.306 | 2.884 | 1.212 |
| Total Current Liabilities
| 95.193 | 73.621 | 73.621 | 79.04 | 28.207 | 10.172 | 4.86 | 2.527 |
| Non-Current Liabilities: | ||||||||
| Long Term Debt
| 225.696 | 196.477 | 88.067 | 87.021 | 58.305 | 31.89 | 0 | 0 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 6.883 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 2.268 | 3.518 | 3.518 | 4.942 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 6.227 | 25.719 | 37.081 | 10.162 | 8.908 | 2.56 | 97.968 | 62.94 |
| Total Non-Current Liabilities
| 234.191 | 225.714 | 225.714 | 130.09 | 97.183 | 34.45 | 97.968 | 62.94 |
| Total Liabilities
| 329.384 | 299.335 | 299.335 | 209.13 | 125.39 | 44.622 | 102.828 | 65.467 |
| Equity: | ||||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 0 | 0 | 97.878 | 62.898 |
| Common Stock
| 0.014 | 0.014 | 0.014 | 0.013 | 0.006 | 0.002 | 0.001 | 0.001 |
| Retained Earnings
| -617.025 | -554.77 | -554.77 | -460.11 | -337.385 | -120.665 | -60.585 | -34.031 |
| Accumulated Other Comprehensive Income/Loss
| -0.025 | -0.023 | -0.023 | -0.031 | 0.006 | -0.052 | -0.44 | -0.268 |
| Other Total Stockholders Equity
| 610.254 | 599.966 | 555.359 | 371.134 | 260.635 | 196.121 | -97.438 | -62.63 |
| Total Shareholders Equity
| -6.782 | 45.187 | 45.187 | 95.231 | 33.761 | 75.406 | -57.83 | -31.934 |
| Total Equity
| -6.782 | 45.187 | 45.187 | 95.231 | 33.761 | 75.406 | -57.83 | -31.934 |
| Total Liabilities & Shareholders Equity
| 322.602 | 344.522 | 344.522 | 304.361 | 159.151 | 120.028 | 44.998 | 33.533 |